文献速递性腺与生殖内分泌垂体与肾上腺疾病

儿童脑肿瘤治疗后的青春期与下丘脑-垂体-性腺轴功能评估

Assessment of Puberty and Hypothalamic-Pituitary-Gonadal Axis Function After Childhood Brain Tumor Treatment.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

该回顾性研究纳入204例18岁前诊断原发性脑肿瘤、于2010年1月至2015年12月在法国巴黎Necker Enfants-Malades大学医院儿科内分泌单元随访的患者,评估其下丘脑-垂体-性腺轴(HPGA)功能并识别受损危险因素。结果显示,未接受放疗的鞍上胶质瘤患者中青春期提前患病率为65%(诊断年龄小于5岁者为70%);髓母细胞瘤化疗导致70%患者性腺毒性(诊断年龄小于5岁者为87.5%);颅咽管瘤组70%存在低促性腺激素性性腺功能减退症,且均伴生长激素缺乏。肿瘤类型、位置和治疗是HPGA受损的主要危险因素。

要点

  • 未放疗的鞍上胶质瘤患者青春期提前患病率65%,诊断年龄<5岁者达70%。
  • 髓母细胞瘤化疗致性腺毒性70%,诊断年龄<5岁者达87.5%。
  • 颅咽管瘤患者70%出现低促性腺激素性性腺功能减退症,均伴生长激素缺乏。

核心结论

  • 肿瘤类型、位置和治疗是HPGA受损的主要危险因素。
  • 认识到起病可能延迟对指导家长和患者信息、患者监测及及时激素替代治疗至关重要。

研究设计与样本

  • 回顾性纳入204例18岁前诊断原发性脑肿瘤、于2010年1月至2015年12月在法国巴黎Necker Enfants-Malades大学医院儿科内分泌单元监测的患者。
  • 排除垂体腺瘤或未治疗胶质瘤患者。

主要发现

  • 未接受放疗的鞍上胶质瘤患者中,青春期提前患病率总体为65%,诊断年龄小于5岁者为70%。
  • 髓母细胞瘤化疗导致全部患者中70%出现性腺毒性,诊断年龄小于5岁者中87.5%出现性腺毒性。
  • 颅咽管瘤组中70%患者存在低促性腺激素性性腺功能减退症,且均伴随生长激素缺乏。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Endocrine complications are common in pediatric brain tumor patients. OBJECTIVE: To describe hypothalamic-pituitary-gonadal axis (HPGA) function in patients treated in childhood for a primary brain tumor more than 5 years earlier, in order to identify risk factors for HPGA impairment. METHODS: We retrospectively included 204 patients diagnosed with a primary brain tumor before 18 years of age and monitored at the pediatric endocrinology unit of the Necker Enfants-Malades University Hospital (Paris, France) between January 2010 and December 2015. Patients with pituitary adenoma or untreated glioma were excluded. RESULTS: Among patients with suprasellar glioma not treated by radiotherapy, the prevalence of advanced puberty was 65% overall and 70% when the diagnosis occurred before 5 years of age. Medulloblastoma chemotherapy caused gonadal toxicity in 70% of all patients and in 87.5% of those younger than 5 years at diagnosis. In the group with craniopharyngioma, 70% of patients had hypogonadotropic hypogonadism, which was consistently accompanied by growth hormone deficiency. CONCLUSION: Tumor type, location, and treatment were the risk main factors for HPGA impairment. Awareness that onset can be delayed is essential to guide information of parents and patients, patient monitoring, and timely hormone replacement therapy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Rosimont M, Kariyawasam D, Samara-Boustani D, et al. Assessment of Puberty and Hypothalamic-Pituitary-Gonadal Axis Function After Childhood Brain Tumor Treatment. J Clin Endocrinol Metab. 2023. PMID: 36810692. doi:10.1210/clinem/dgad097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。